Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review.

Content Provider	Europe PMC
Author	Rinaldi, Ikhwan Winston, Kevin
Copyright Year	2023
Abstract	AbstractChronic myeloid leukemia (CML) is one of the most common leukemias occurring in the adult population. The course of CML is divided into three phases: the chronic phase, the acceleration phase, and the blast phase. Pathophysiology of CML revolves around Philadelphia chromosome that constitutively activate tyrosine kinase through BCR-ABL1 oncoprotein. In the era of tyrosine kinase inhibitors (TKIs), CML patients now have a similar life expectancy to people without CML, and it is now very rare for CML patients to progress to the blast phase. Only a small proportion of CML patients have resistance to TKI, caused by BCR-ABL1 point mutations. CML patients with TKI resistance should be treated with second or third generation TKI, depending on the BCR-ABL1 mutation. Recently, many studies have shown that it is possible for CML patients who achieve a long-term deep molecular response to stop TKIs treatment and maintain remission. This review aimed to provide an overview of CML, including its pathophysiology, clinical manifestations, the role of stem cells, CML treatments, and treatment-free remission.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10084831&blobtype=pdf
Page Count	17
Journal	Journal of Blood Medicine [J Blood Med]
Volume Number	14
PubMed Central reference number	PMC10084831
PubMed reference number	37051025
e-ISSN	11792736
DOI	10.2147/jbm.s382090
Language	English
Publisher	Dove
Publisher Date	2023-04-06
Access Restriction	Open
Rights License	This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2023 Rinaldi and Winston.
Subject Keyword	chronic myeloid leukemia remission tyrosine kinase inhibitor
Content Type	Text
Resource Type	Article
Subject	Hematology